WIC
AKRO

Woodmont Investment Counsel’s Akero Therapeutics AKRO Stock Holding History

Woodmont Investment Counsel’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-6,620
Closed -$335K – 241
2023
Q3 		$335K Hold
6,620
– – 0.04% 187
2023
Q2 		$309K Sell
6,620
-500
-7% -$22.9K 0.03% 193
2023
Q1 		$272K Sell
7,120
-450
-6% -$20.1K 0.03% 210
2022
Q4 		$415K Sell
7,570
-2,050
-21% -$87.8K 0.05% 184
2022
Q3 		$328K Sell
9,620
-2,500
-21% -$38.3K 0.04% 197
2022
Q2 		$115K Buy
12,120
+2,000
+20% +$20.9K 0.01% 235
2022
Q1 		$144K Buy
10,120
+500
+5% +$8.76K 0.02% 241
2021
Q4 		$203K Buy
+9,620
New +$213K 0.03% 212

Other funds holding AKRO

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Woodmont Investment Counsel's AKRO Position: Q4 2023 in Review

Woodmont Investment Counsel sold out of Akero Therapeutics (AKRO) in Q4 2023, closing a stake of 6,620 shares — an estimated $335K sold.

Woodmont Investment Counsel first reported a position in AKRO in Q4 2021 and held it in 8 quarters. The position peaked at $415K in Q4 2022. 157 funds tracked by Wall St. Rank hold AKRO as of Q4 2023.

  • Woodmont Investment Counsel reported no remaining Akero Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Woodmont Investment Counsel sold 6,620 Akero Therapeutics shares in Q4 2023, an estimated $335K.
  • Woodmont Investment Counsel first reported a position in Akero Therapeutics in Q4 2021 and held it in 8 quarters.
  • Woodmont Investment Counsel's Akero Therapeutics position peaked at $415K in Q4 2022.
  • 157 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2023.

Based on Woodmont Investment Counsel's 13F filing for Q4 2023, filed 19 Jan 2024.